Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Ann R FalseyMagdalena E SobieszczykIan HirschStephanie SprouleMerlin L RobbLawrence CoreyKathleen M NeuzilWilliam HahnJulie HuntMark J MulliganCharlene McEvoyEdwin DeJesusMichael HassmanSusan J LittleBarbara A PahudAnna DurbinPaul PickrellEric S DaarLarry BushJoel SolisQuito Osuna CarrTemitope OyedeleSusan BuchbinderJessica CowdenSergio L VargasAlfredo Guerreros BenavidesRobert CallMichael C KeeferBeth D KirkpatrickJohn PullmanTina TongMargaret Brewinski IsaacsDavid C BenkeserHolly E JanesMartha C NasonJustin A GreenElizabeth J KellyJill MaaskeNancy MuellerKathryn ShoemakerTherese TakasRichard P MarshallMenelas N PangalosTonya VillafanaAntonio Gonzalez-Lopeznull nullPublished in: The New England journal of medicine (2021)
AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).